NUP50-DT: A Potential Drug Target and Biomarker (G100506714)

Target Name: NUP50-DT

NCBI ID: G100506714

NUP50-DT

Other Name(s): NUP50 divergent transcript, transcript variant 1 | NUP50-AS1 | NUP50 divergent transcript | NUP50-DT variant 1

NUP50-DT: A Potential Drug Target and Biomarker

NUP50 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and heart. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The discovery of NUP50 as a potential drug target and biomarker has significant implications for the development of new treatments for these diseases.

The NUP50 protein is composed of 50 amino acid residues and has a calculated molecular weight of 61 kDa. It is located in the cytoskeleton and is involved in the regulation of cell adhesion, as well as the formation of tight junctions and the development of tissues. NUP50 has been shown to play a role in a number of important biological processes, including the development and progression of cancer, the regulation of neurotransmitter release, and the regulation of cell survival.

One of the key challenges in studying NUP50 is its high degree of homogeneity, as there is little information about the structure and function of the protein in different species. However, research has identified a number of potential interacting partners and regulators, including the transcription factor NF-kappa-B and the protein kinase PDK4. These interactions suggest that NUP50 may play a role in a number of important cellular processes, including cell signaling, protein synthesis, and cell survival.

In addition to its potential drug target and biomarker properties, NUP50 is also of interest as a potential therapeutic agent for a number of diseases. For example, NUP50 has been shown to be overexpressed in a variety of cancer types, including breast, ovarian, and colorectal cancer. This suggests that targeting NUP50 may be a promising strategy for the development of new cancer therapies. Additionally, NUP50 has been shown to play a role in the regulation of neurotransmitter release and has been implicated in a number of neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Therefore, targeting NUP50 may also be a promising strategy for the development of new treatments for these diseases.

In conclusion, NUP50 is a protein that has significant implications as a potential drug target and biomarker. Its high degree of homogeneity and its potential interacting partners and regulators make it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of NUP50 in cellular processes and its potential as a therapeutic agent.

Protein Name: NUP50 Divergent Transcript

The "NUP50-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP50-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets